Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Celebrating a Century of Discovery.

Archives of pathology & laboratory medicine·2025
Same author

Pathology of COVID-19 Lung Disease.

Surgical pathology clinics·2024
Same author

Thoracic Pathology-Learning from the Past to Inform the Future.

Surgical pathology clinics·2024
Same author

Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate Staging.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2024
Same author

A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer.

Cell reports. Medicine·2024
Same author

Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.

Nature communications·2024

Related Experiment Video

Updated: Jun 27, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Molecular Testing in Lung Cancer: Recommendations and Update.

Alain C Borczuk1

  • 1Anatomic Pathology, Northwell Health, 2200 Northern Boulevard Suite 104, Greenvale, NY 11548, USA.

Surgical Pathology Clinics
|May 1, 2024
PubMed
Summary

Molecular testing is crucial for lung cancer diagnosis and targeted therapy. Pathologists must optimize testing strategies, especially with limited tissue, to ensure timely and comprehensive patient assessment.

Keywords:
AdenocarcinomaLungMolecular testingTissue stewardship

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K

Related Experiment Videos

Last Updated: Jun 27, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K

Area of Science:

  • Oncology
  • Pathology
  • Molecular Diagnostics

Background:

  • Molecular testing is increasingly adopted in lung cancer management.
  • Key indications include staging and predicting response to targeted therapies.
  • Both tissue specimens and blood-based testing are vital, with cytology also playing a role.

Purpose of the Study:

  • To highlight the importance of optimizing molecular testing strategies in lung cancer.
  • To emphasize the role of pathologists in ensuring timely and complete assessments.
  • To address challenges associated with limited tissue samples.

Main Methods:

  • Review of current practices in lung cancer molecular testing.
  • Discussion of diagnostic algorithms and test selection.
  • Consideration of strategies for limited tissue specimens.

Main Results:

  • Molecular testing is essential for personalized lung cancer treatment.
  • Pathologists play a critical role in test optimization and interpretation.
  • Effective strategies are needed to maximize information from limited tissue.

Conclusions:

  • Optimizing reflex testing and utilizing stage-based algorithms are crucial for pathologists.
  • When tissue is limited, prioritizing common, mutually exclusive alterations maximizes diagnostic yield.
  • Avoiding repeat biopsies through strategic testing is a key objective.